Oral anticoagulant treatment of patients with cardioembolic stroke with unchanged or reassigned subtype
| Treatment | Consistent CE* (n=282) | Centrally reassigned CE† (n=262) | Newly diagnosed CE‡ (n=447) | ||||||
| With indication§ n=270 | Without indication n=12 | P value | With indication§ n=161 | Without indication n=101 | P value | With indication§ n=300 | Without indication n=147 | P value | |
| In-hospital anticoagulant | 151 (55.9%) | 4 (33.3%) | 0.146 | 86 (53.4%) | 18 (17.8%) | <0.0001 | 82 (27.3%) | 12 (8.2%) | <0.0001 |
| Warfarin | 89/151 to 58.9% | 3/4 to 75.0% | 0.647 | 46/86 to 53.5% | 5/18 to 27.8% | 0.069 | 26/82 to 31.7% | 1/12 to 8.3% | 0.169 |
| LWHP | 80/151 to 53.0% | 1/4 to 25.0% | 0.349 | 49/86 to 57.0% | 9/18 to 50.0% | 0.611 | 43/82 to 52.4% | 8/12 to 66.7% | 0.537 |
| Heparin | 1/151 to 0.7% | 0/4 to 0% | 1.000 | 4/18 to 22.2% | 0/86 to 0% | <0.001 | 1/82 to 1.2% | 0/12 to 0% | 1.000 |
| Rivaroxaban | 9/151 to 6.0% | 0/4 to 0% | 1.000 | 2/86 to 2.3% | 0/18 to 0% | 1.000 | 2/82 to 2.4% | 0/12 to 0% | 1.000 |
| Dabigatran | 22/151 to 14.6% | 1/4 to 25.0% | 0.478 | 6/86 to 7.0% | 1/18 to 5.6% | 1.000 | 5/82 to 6.1% | 0/12 to 0% | 1.000 |
| Apixaban | 0/151 to 0% | 0/4 to 0% | NE | 0/86 to 0% | 0/18 to 0% | NE | 0/82 to 0% | 0/12 to 0% | NE |
| Others | 4/151 to 2.7% | 0/4 to 0% | 1.000 | 2/86 to 2.3% | 1/18 to 5.6% | 0.438 | 11/82 to 13.4% | 3/12 to 25.0% | 0.379 |
| Treatment | Consistent CE¶ (n=283) | Centrally reassigned CE** (n=261) | Newly diagnosed CE†† (n=448) | ||||||
| With indication§ n=271 | Without indication n=12 | P value | With indication§ n=157 | Without indication n=104 | P value | With indication§ n=300 | Without indication n=148 | P value | |
| Discharge anticoagulant | 139 (51.3%) | 4 (33.3%) | 0.252 | 66 (42.0%) | 8 (7.7%) | <0.0001 | 46 (15.3%) | 2 (1.4%) | <0.0001 |
| Warfarin | 103/139 to 74.1% | 3/4 to 75.0% | 1.000 | 53/66 to 80.3% | 7/8 to 87.5% | 1.000 | 33/46 to 71.7% | 1/2 to 50.0% | 0.503 |
| LWHP | 0/139 to 0% | 0/4 to 0% | NE | 2/66 to 3.0% | 1/8 to 12.5% | 0.294 | 2/46 to 4.4% | 1/2 to 50.0% | 0.122 |
| Heparin | 0/139 to 0% | 0/4 to 0% | NE | 0/66 to 0% | 0/8 to 0% | NE | 0/46 to 0% | 0/2 to 0% | NE |
| Rivaroxaban | 8/139 to 5.8% | 0/4 to 0% | 1.000 | 4/66 to 6.1% | 1/8 to 12.5% | 0.445 | 4/46 to 8.7% | 0/2 to 0% | 1.000 |
| Dabigatran | 27/139 to 19.4% | 1/4 to 25.0% | 1.000 | 7/66 to 10.6% | 0/8 to 0% | 1.000 | 7/46 to 15.2% | 0/2 to 0% | 1.000 |
| Apixaban | 0/139 to 0% | 0/4 to 0% | NE | 0/66 to 0% | 0/8 to 0% | NE | 0/46 to 0% | 0/2 to 0% | NE |
| Others | 1/139 to 0.7% | 0/4 to 0% | 1.000 | 0/66 to 0% | 0/8 to 0% | NE | 0/46 to 0% | 0/2 to 0% | NE |
*Missing data of two patients.
†Missing data of four patients.
‡Missing data of two patients.
§Indications of oral anticoagulation treatment included mechanical prosthetic valve, mitral stenosis with atrial fibrillation, atrial fibrillation, left atrial/atrial appendage thrombus, left ventricular thrombus and atrial flutter.
¶Missing data of one patient.
**Missing data of five patients.
††Missing data of one patient.
CE, cardioembolism; LWHP, low molecular weight heparin; NE, not estimable.